JP7475283B2 - キレート化された放射性核種に対する抗体 - Google Patents

キレート化された放射性核種に対する抗体 Download PDF

Info

Publication number
JP7475283B2
JP7475283B2 JP2020556869A JP2020556869A JP7475283B2 JP 7475283 B2 JP7475283 B2 JP 7475283B2 JP 2020556869 A JP2020556869 A JP 2020556869A JP 2020556869 A JP2020556869 A JP 2020556869A JP 7475283 B2 JP7475283 B2 JP 7475283B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020556869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520832A (ja
JP2021520832A5 (https=
JPWO2019201959A5 (https=
Inventor
クリスティアン クライン，
パブロ ウマーナ，
アレクサンダー ハース，
バルバラ ヴァイザー，
フロリアン リップスマイヤー，
ギー ジョルジュ，
セバスチャン フェン，
イェルク メレケン，
フェリックス ボルマン，
ダニエラ マチェコ，
Original Assignee
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2021520832A publication Critical patent/JP2021520832A/ja
Publication of JP2021520832A5 publication Critical patent/JP2021520832A5/ja
Publication of JPWO2019201959A5 publication Critical patent/JPWO2019201959A5/ja
Priority to JP2024003062A priority Critical patent/JP2024056687A/ja
Application granted granted Critical
Publication of JP7475283B2 publication Critical patent/JP7475283B2/ja
Priority to JP2025244101A priority patent/JP2026062683A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
JP2020556869A 2018-04-16 2019-04-16 キレート化された放射性核種に対する抗体 Active JP7475283B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024003062A JP2024056687A (ja) 2018-04-16 2024-01-12 キレート化された放射性核種に対する抗体
JP2025244101A JP2026062683A (ja) 2018-04-16 2025-12-10 キレート化された放射性核種に対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658468P 2018-04-16 2018-04-16
US62/658,468 2018-04-16
PCT/EP2019/059856 WO2019201959A1 (en) 2018-04-16 2019-04-16 Antibodies for chelated radionuclides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024003062A Division JP2024056687A (ja) 2018-04-16 2024-01-12 キレート化された放射性核種に対する抗体

Publications (4)

Publication Number Publication Date
JP2021520832A JP2021520832A (ja) 2021-08-26
JP2021520832A5 JP2021520832A5 (https=) 2022-04-26
JPWO2019201959A5 JPWO2019201959A5 (https=) 2022-04-26
JP7475283B2 true JP7475283B2 (ja) 2024-04-26

Family

ID=66476592

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020556869A Active JP7475283B2 (ja) 2018-04-16 2019-04-16 キレート化された放射性核種に対する抗体
JP2024003062A Withdrawn JP2024056687A (ja) 2018-04-16 2024-01-12 キレート化された放射性核種に対する抗体
JP2025244101A Pending JP2026062683A (ja) 2018-04-16 2025-12-10 キレート化された放射性核種に対する抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024003062A Withdrawn JP2024056687A (ja) 2018-04-16 2024-01-12 キレート化された放射性核種に対する抗体
JP2025244101A Pending JP2026062683A (ja) 2018-04-16 2025-12-10 キレート化された放射性核種に対する抗体

Country Status (31)

Country Link
US (2) US20220389116A1 (https=)
EP (2) EP4406607A3 (https=)
JP (3) JP7475283B2 (https=)
KR (1) KR102884852B1 (https=)
CN (1) CN112261952A (https=)
AR (1) AR115053A1 (https=)
AU (1) AU2019254537B2 (https=)
BR (1) BR112020021061A2 (https=)
CA (1) CA3096338A1 (https=)
CL (1) CL2020002680A1 (https=)
CR (1) CR20200548A (https=)
DK (1) DK3781200T3 (https=)
ES (1) ES2985352T3 (https=)
FI (1) FI3781200T3 (https=)
HR (1) HRP20241013T1 (https=)
HU (1) HUE067622T2 (https=)
IL (1) IL277575B2 (https=)
LT (1) LT3781200T (https=)
MA (1) MA52545B1 (https=)
MX (1) MX2020010954A (https=)
MY (1) MY207044A (https=)
PE (1) PE20210442A1 (https=)
PL (1) PL3781200T3 (https=)
PT (1) PT3781200T (https=)
RS (1) RS65753B1 (https=)
SG (1) SG11202010066TA (https=)
SI (1) SI3781200T1 (https=)
TW (1) TWI874314B (https=)
UA (1) UA130541C2 (https=)
WO (1) WO2019201959A1 (https=)
ZA (1) ZA202006121B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
AR119382A1 (es) * 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
JP2023533533A (ja) 2020-07-10 2023-08-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、当該細胞に対して放射性ヌクレオチドを標的化する抗体
EP4277705A1 (en) 2021-01-12 2023-11-22 F. Hoffmann-La Roche AG Split antibodies which bind to cancer cells and target radionuclides to said cells
US20240173442A1 (en) 2021-01-13 2024-05-30 Hoffmann-La Roche Inc. Combination therapy
EP4448565A1 (en) 2021-12-15 2024-10-23 Y-Mabs Therapeutics, Inc. Scfv and antibodies with reduced multimerisation
CN120152992A (zh) 2022-11-08 2025-06-13 Y-单克隆抗体制药有限公司 双特异性抗体化合物
WO2025176614A1 (en) 2024-02-20 2025-08-28 F. Hoffmann-La Roche Ag Novel pre-targeting antibodies and uses thereof
WO2026041568A1 (en) 2024-08-20 2026-02-26 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and dotam

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505861A (ja) 2014-12-23 2018-03-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物
JP2021521245A (ja) 2018-04-16 2021-08-26 オラノ メド エスアエス キレート化された放射性核種に対する抗体および除去剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016012830A (es) * 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
MX2017010072A (es) * 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
CA2976074A1 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
EP3356410B1 (en) * 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505861A (ja) 2014-12-23 2018-03-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物
JP2021521245A (ja) 2018-04-16 2021-08-26 オラノ メド エスアエス キレート化された放射性核種に対する抗体および除去剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Damian J. GREEN et al.，"Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers"，Cancer Research，2016年11月14日，Vol. 76, No. 22，p.6669-6679，DOI:10.1158/0008-5472.CAN-16-0571
P． J. YAZAKI et al.，"A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting:comparison of tumor uptake and blood clearance"，ProteinEngineering Design and Selection，2012年11月21日，Vol. 26, No. 3，p.187-193，DOI:10.1093/protein/gzs096

Also Published As

Publication number Publication date
IL277575B2 (en) 2025-11-01
IL277575A (en) 2020-11-30
JP2021520832A (ja) 2021-08-26
HUE067622T2 (hu) 2024-10-28
RS65753B1 (sr) 2024-08-30
TW202011987A (zh) 2020-04-01
UA130541C2 (uk) 2026-03-18
WO2019201959A1 (en) 2019-10-24
MA52545A (fr) 2021-02-24
JP2024056687A (ja) 2024-04-23
HRP20241013T1 (hr) 2024-10-25
BR112020021061A2 (pt) 2021-02-17
MA52545B1 (fr) 2024-08-30
US20220389116A1 (en) 2022-12-08
AR115053A1 (es) 2020-11-25
ZA202006121B (en) 2025-05-28
KR20210005885A (ko) 2021-01-15
PL3781200T3 (pl) 2024-09-16
FI3781200T3 (fi) 2024-07-31
CR20200548A (es) 2021-01-20
PT3781200T (pt) 2024-07-19
TWI874314B (zh) 2025-03-01
MX2020010954A (es) 2020-11-09
US20260015436A1 (en) 2026-01-15
CA3096338A1 (en) 2019-10-24
KR102884852B1 (ko) 2025-11-14
AU2019254537B2 (en) 2025-06-19
DK3781200T3 (da) 2024-08-05
CN112261952A (zh) 2021-01-22
AU2019254537A1 (en) 2020-10-29
EP3781200A1 (en) 2021-02-24
CL2020002680A1 (es) 2021-02-12
EP4406607A2 (en) 2024-07-31
PE20210442A1 (es) 2021-03-08
EP3781200B1 (en) 2024-05-29
MY207044A (en) 2025-01-27
EP4406607A3 (en) 2024-10-16
JP2026062683A (ja) 2026-04-10
SG11202010066TA (en) 2020-11-27
ES2985352T3 (es) 2024-11-05
LT3781200T (lt) 2024-08-12
SI3781200T1 (sl) 2024-09-30
IL277575B1 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
JP7475283B2 (ja) キレート化された放射性核種に対する抗体
JP7582867B2 (ja) キレート化された放射性核種に対する抗体および除去剤
JP2026000913A (ja) がん細胞に結合し、放射性核種を前記細胞にターゲティングする抗体
US20230272116A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
US20240082437A1 (en) Split antibodies which bind to cancer cells and target radionuclides to said cells
RU2833233C2 (ru) Антитела к хелатным радионуклидам
HK40063708A (en) Antibodies which bind to cancer cells and target radionuclides to said cells
HK40042318A (en) Antibodies for chelated radionuclides and clearing agents
HK40042319A (en) Antibodies for chelated radionuclides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240416

R150 Certificate of patent or registration of utility model

Ref document number: 7475283

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150